ClinicalTrials.gg
CompletedNCT04444167Updated Apr 25, 2024

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

A Phase 1/2 interventional study of AK104 and Lenvatinib in Hepatocellular Carcinoma, sponsored by Akeso. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-25.

Sponsored by Akeso · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
59
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing cadonilimab in Carcinoma, Hepatocellular — 13 open to participants now, 16 under way, 2 of them phase 3. cadonilimab · Carcinoma, Hepatocellular.

Enrollment
7th of 23
59 · median 36
Started
2020
the only one that year
Phase 1/2
2 of 23
1 open now
Registered
1st of 23
by date
Lead sponsor
6 of 23
Akeso

Among the 23 studies testing cadonilimab in Carcinoma, Hepatocellular, this one is the 7th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1/2, and was the 1st registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

13 of the 23 studies testing cadonilimab in Carcinoma, Hepatocellular are open now, in 2 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

About cadonilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing cadonilimab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

An open-label multi-center phase Ib/II study to evaluate the efficacy and safety of anti-PD-1/CTLA-4 bispecific antibody AK104 plus lenvatinib as the first-line therapy for patients with advanced hepatocellular carcinoma.

Read the detailed description

This is a multi-center, multi-cohort, open-label phase 1b/2 clinical study to evaluate the anti-tumor activity, safety, PK profile, immunogenicity and potential biomarkers of AK104 plus lenvatinib for the treatment of advanced hepatocellular carcinoma.

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • VEGF
  • Anti-PD-1
  • Tyrosine Kinase Inhibitor (TKI)
  • Anti-CTLA-4
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written form voluntarily.
  • or cytologically documented hepatocellular carcinoma.
  • BCLC stage C, and non-resectable BCLC stage B .
  • At least one according to criteria.
  • of 0 or 1.
  • Adequate organ function.
  • Estimated of ≥3 months.
  • For women of : agreement to remain abstinent; For men: agreement to remain abstinent.

Exclusion criteria

Exclusion Criteria:

  • or cytologically documented fibrolamellar hepatocellular carcinoma, sarcoma-like hepatocellular carcinoma, cholangiocarcinoma, etc.
  • History of hepatic encephalopathy or liver transplantation.
  • Clinical significance of hydrothorax, ascites or pericardial effusion.
  • Central nervous system and/or carcinomatous meningitis.
  • Any risk of bleeding; severe bleeding tendency or coagulation dysfunction, or under thrombolytic therapy.
  • Occurred arteriovenous thromboembolic events within 6 months before the first administration.
  • Tumor volume > 50% liver volume; portal vein tumor thrombus or inferior vena cava tumor thrombus.
  • Inadequately controlled arterial hypertension.
  • Attack of symptomatic congestive heart failure (\<50%); History of congenital long syndrome.
  • Known presence or history of interstitial lung disease or required hormone treatment interstitial lung disease.
  • Severe infections.
  • Receipt of any anti-tumor treatment, chemotherapy, targeted therapy, immunotherapy,
  • Enrollment of another clinical study within 4 weeks prior to the first administration of study drugs.
  • Unable to receive an enhanced CT or MRI scan of the liver.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    AK104 and Lenvatinib

    AK104 6 mg/kg IV every 2 weeks (Q2W) Lenvatinib 12mg weight≥60kg or 8mg weight\<60kg,PO QD

    Biological: AK104 · Drug: Lenvatinib

Interventions

  • BiologicalAK104

    Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months

  • Subjects will receive AK104 and lenvatinib until disease progression for a maximum of 24 months

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    ORR is defined as the proportion of subjects with confirmed CR or PR, based on RECIST v1.1.

    Time frame: Up to 2 years

Secondary outcomes

  1. Disease control rate (DCR)

    The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥8 weeks) based on RECIST Version 1.1.

    Time frame: Up to 2 years

  2. Duration of response (DoR)

    Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first

    Time frame: Up to 2 years

  3. Progression-free survival (PFS)

    Progression-free survival is defined as the time from the start of treatment with AK104 until the first documentation of disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to 2 years

  4. Number of participants with adverse events (AEs)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: the time of informed consent signed through 90 days after the last dose of AK104 and

  5. Observed concentrations of AK104

    The endpoints for assessment of PK of AK104 include serum concentrations of AK104 at different timepoints after AK104 administration.

    Time frame: From first dose of AK104 through 90 days after last dose of AK104

  6. Number of subjects who develop detectable anti-drug antibodies (ADAs)

    The immunogenicity of AK104 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs).

    Time frame: From first dose of AK104 through 90 days after last dose of AK104

07

Study locations

1 site
  • Chinese PLA General Hospital
    Beijing, Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Nov 2023, 40 months.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's 40 months is below that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2020
First posted
Jun 23, 2020
StartActual
Jul 7, 2020
Primary completionActual
Nov 20, 2023
CompletionActual
Nov 20, 2023
Last update
Apr 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04444167
Lead sponsor
Akeso
Collaborators
Akeso Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jun 23, 2020
Start date
Jul 7, 2020
Primary completion
Nov 20, 2023
Completion
Nov 20, 2023
Last update
Apr 25, 2024

Study contacts

Li Bai, MD
principal investigator · Chinese PLA General Hospital
Shunchang Jiao, MD
principal investigator · Chinese PLA General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cadonilimab

Start the discussion